Navigation Links
Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
Date:6/22/2011

SALT LAKE CITY, June 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today formally announced an approximately $44 million expansion of its Salt Lake City, Utah, Watson Laboratories, Inc. site. This facility is Watson's state-of-the-art pharmaceutical research, development and manufacturing facility for transdermal patches and topical gels.  Governor Gary R. Herbert toured the facility and participated with Watson's President and Chief Executive Officer, Paul Bisaro, in ceremonies marking the expansion.  

The Salt Lake City expansion includes retrofitting approximately 20,000 square feet of existing space and the construction of approximately 17,000 square feet of future manufacturing space.  The Company anticipates the expansion could ultimately result in the addition of approximately 300 employees within the next 3-5 years. The expansion supports a potential tripling in annual manufacturing batch capacity to support future new products, including the generic version of the Lidoderm® transdermal pain management product, which the Company may launch as early as mid to late 2012.  It will also support Watson's expansion of transdermal and topical gel products manufactured in Salt Lake City into select international markets.  

"We are committed to expanding our presence in Salt Lake City, which is our center of excellence for the manufacture of brand and generic pharmaceutical products that utilize topical or transdermal patch drug delivery technologies.  This expansion not only supports our near-term product manufacturing and packaging needs, but also positions us to more efficiently meet anticipated future consumer demand for products that are currently in various stages of development," said Paul Bisaro, President and CEO.  

"This expansion is more than just bricks and mortar.  We are investing in the creation of skilled manufacturing, packaging and quality control/quality assurance and other jobs that will create opportunities for the population of Salt Lake City and the surrounding areas.  We are delighted to have Governor Herbert join us in commemorating Watson's significant investment in the future of our Company and in the future of the Salt Lake City community."

Watson's Salt Lake City facility is the headquarters for the Company's Global Brands research and development operations, with approximately 175 professionals involved in product development.  In addition, the Salt Lake City facility manufactures and packages brand and generic transdermal patch and topical gel pharmaceutical products, and currently employs more than 200 people in manufacturing and operations.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking StatementStatements contained in this press release that refer to Watson's estimated or anticipated financial results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's product development activities, product introductions, product launch timing, and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and U.S. Food and Drug Administration (FDA) or other regulatory agency approvals or actions, if any; the difficulty of predicting the timing or outcome of patent litigation related to Watson's pending abbreviated new drug application for a generic version of the Lidoderm® transdermal pain management product, and risks that an adverse outcome in such litigation following its launch could render Watson liable for substantial damages; risks that competitors may seek to delay or prevent product approvals through legislative, regulatory or other means; risks that the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful consummation and implementation of strategic initiatives, including the expansion of the Salt Lake City, Utah, site; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; changes in generally accepted accounting principles; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the period ended December 31, 2010, and Watson's quarterly report on Form 10-Q for the period ended March 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Lidoderm® is a registered trademark of Hind Healthcare, Inc.CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
2. Watson Confirms AVODART(R) Patent Challenge
3. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
4. Watsons Nabumetone Tablets Receive FDA Approval
5. Watson Confirms Pataday™ Patent Challenge
6. Watson Confirms Viagra® Patent Challenge
7. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
8. Watson Launches Generic AMRIX®
9. Watson Launches Generic Concerta®
10. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
11. Watson First Quarter 2011 Net Revenue Increases to $877 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):